Taltz in Combination With Enstilar for Psoriasis

StatusRecruiting
PhasePhase 4
Started

Record status This record was last updated May 4, 2020 (before its estimated March 1, 2021 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Enstilar in combination with Taltz for plaque psoriasis.
Trial Details
NCT Number NCT04372277
Lead Sponsor Psoriasis Treatment Center of Central New Jersey
Collaborators: Eli Lilly and Company
Conditions
(from sponsor)
Psoriasis
Related terms Psoriasis
Enrollment 25 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov